首页|Clinicopathological Features and Long-Term Prognostic Role of Human Epidermal Growth Factor Receptor-2 Low Expression in Chinese Patients with Early Breast Cancer:A Single-Institution Study

Clinicopathological Features and Long-Term Prognostic Role of Human Epidermal Growth Factor Receptor-2 Low Expression in Chinese Patients with Early Breast Cancer:A Single-Institution Study

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective This study aimed to comprehensively analyze and compare the clinicopathological features and prognosis of Chinese patients with human epidermal growth factor receptor 2(HER2)-low early breast cancer(BC)and HER2-IHC0 BC.Methods Patients diagnosed with HER2-negative BC(N=999)at our institution between January 2011 and December 2015 formed our study population.Clinicopathological characteristics,association between estrogen receptor(ER)expression and HER2-low,and evolution of HER2 immunohistochemical(IHC)score were assessed.Kaplan-Meier method and log-rank test were used to compare the long-term survival outcomes(5-year follow-up)between the HER2-IHC0 and HER2-low groups.Results HER2-low BC group tended to demonstrate high expression of ER and more progesterone receptor(PgR)positivity than HER2-IHC0 BC group(P<0.001).The rate of HER2-low status increased with increasing ER expression levels(Mantel-Haenszel χ2 test,P<0.001,Pearson's R=0.159,P<0.001).Survival analysis revealed a significantly longer overall survival(OS)in HER2-low BC group than in HER2-IHC0 group(P=0.007)in the whole cohort and the hormone receptor(HR)-negative group.There were no significant differences between the two groups in terms of disease-free survival(DFS).The discordance rate of HER2 IHC scores between primary and metastatic sites was 36.84%.Conclusion HER2-low BC may not be regarded as a unique BC group in this population-based study due to similar clinicopathological features and prognostic roles.

HER2HER2-lowBreast cancerEstrogen receptorTrastuzumab deruxtecan

KONG Zi Qing、LIU Li Qun、HUANG De Qin、WANG Yu Tong、LI Jing Jie、ZHANG Zheng、WANG Xi Xi、LIU Chuan Ling、ZHANG Ya Di、SHAO Jia Kang、ZHU Yi Min、CHEN Yi Meng、LIU Mei、ZHAO Wei Hong

展开 >

Medical School of Chinese PLA,Beijing 100853,China

Department of Medical Oncology,the First Medical Center,General Hospital of the Chinese People's Liberation Army,Beijing 100853,China

Nankai University School of Medicine,Tianjin 300071,China

Department of Medical Oncology,the Fifth Medical Center,General Hospital of the Chinese People's Liberation Army,Beijing 100039,China

Department of Medical Oncology,Xi'an Jiaotong University,Xi'an 710061,Shaanxi,China

Department of Pathology,the Sixth Medical Center,General Hospital of the Chinese People's Liberation Army,Beijing 100037,China

展开 >

Health Care Special Project

17BJZ40

2024

10.3967/bes2024.014

生物医学与环境科学(英文版)
中国疾病预防控制中心

生物医学与环境科学(英文版)

CSTPCD
影响因子：0.76
ISSN：0895-3988
年,卷(期)：2024.37(5)